Tritazide 2,5 mg/12,5 mg tablete
Name | Tritazide 2,5 mg/12,5 mg tablete |
---|---|
Marketing Authorisation Number | HR-H-290180500 |
Active Substance | ramipril hidroklorotiazid |
Composition | jedna tableta sadrži 2,5 mg ramiprila i 12,5 mg hidroklorotiazida |
Pharmaceutical Form | tableta |
Manufacturer | Sanofi S.r.l., Scoppito (L'Aquila), Italija |
Marketing Authorisation Holder | Sanofi Winthrop Industrie, 82, avenue Raspail, Gentilly, Francuska |
Marketing Authorisation Date | 01.09.2023 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/16-02/200 |
Registration Number | 381-12-01/286-23-57 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | C09BA05 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |
Packaging
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |